Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic
Zoë YGJ van Lierop, Mark HJ Wessels, Womei ML Lekranty, Bastiaan Moraal, Sam N Hof, Laura Hogenboom, Brigit A. de Jong, Nandi Meijs, Liselore A. Mensing, Bob W. van Oosten, Nik Sol, Zoé L. E. van Kempen, Lisa Vermunt, Myrthe Willems, Eva Strijbis, Bernard M.J. Uitdehaag, Joep Killestein, Charlotte E. Teunissen
Abstract
Background and objectives: Serum neurofilament light (sNfL) is a biomarker for neuro-axonal damage in multiple sclerosis (MS). Clinical implementation remains limited. We investigated the impact of implementation on clinical decisions using questionnaires at the MS Center Amsterdam, a tertiary outpatient clinic. Methods: sNfL assessments were added to routine clinical practice (August 2021–December 2022). Before and after the results, clinicians filled in questionnaires on context of testing, clinical decisions, certainty herein, expectation of magnetic resonance imaging (MRI) activity, urgency, and motivation to receive the sNfL result and perceived value of sNfL. Results: sNfL was assessed in 166 cases (age 41 ± 12 years, 68% female, 64% disease-modifying therapy (DMT) use) for the following contexts: “DMT monitoring” (55%), “new symptoms” (18%), “differential diagnosis” (17%), and “DMT baseline” (11%). Clinical decisions changed in 19.3% of cases post-disclosure, particularly in context “new symptoms” (38%) and with higher sNfL levels (β = 0.03, p = 0.04). Certainty increased ( p = 0.004), while expectation of MRI activity decreased with disclosure of low sNfL levels ( p = 0.01). Motivation was highest in context “differential diagnosis” ( p < 0.001); perceived value and urgency were highest in context “new symptoms” ( p = 0.02). Conclusion: In this study, sNfL implementation had considerable impact on clinical decision-making and certainty herein. Standard implementation may complement patient care but warrants caution and more exploration in diverse clinical settings